Resource Center
Resource Center
Treating severe malaria with injectable artesunate instead of quinine can substantially reduce mortality. To increase uptake and improve health outcomes, CHAI supported ministries of health in six high-burden countries to overcome barriers to adoption. Learn more about CHAI’s work to increase update and reduce severe malaria mortality in this case study.
Read more
Access to better tolerated, more convenient regimens for HIV treatment promotes adherence and leads to better patient outcomes. CHAI is working to ensure affordable pricing and to address demand-side barriers to access. Increased uptake of optimal second-line regimens in Uganda and Nigeria has improved HIV treatment and will deliver US$6.5 million in savings by 2018....
Read more
CHAI and partners achieved a price reduction agreement for contraceptive implants that increased total implant distribution by 56 percent from 2012 to 2013 and will result in procurement savings of more than US$300 million over six years. Learn more about this agreement to expand access to contraceptive implants and improve women’s choice and well-being in...
Read more
Achieving universal access to HIV treatment requires using the resources available as efficiently as possible. To this end, CHAI supports 10 countries to conduct annual resource mapping. In Malawi, results have informed the allocation of US$300 million to high-impact interventions and increased national ownership of the HIV response. Learn more about CHAI’s work improving efficiency...
Read more
Viral hepatitis is a major public health problem throughout the world, killing more people every year than HIV.(i) Hepatitis C is a viral disease transmitted through infected bodily fluids and attacks the liver, slowly scarring the organ until the person acquires liver cancer or faces a number of other renal or hepatic conditions that diminish...
Read more
CHAI and global partners in the Diagnostics Access Initiative have joined with Roche Diagnostics to announce a 35 percent reduction in the price for HIV early infant diagnostic technologies. The new access price is US$9.40 per test, including proprietary reagents and consumables associated with diagnosing HIV in very young children. Learn more here.
Read more
CHAI’s Research and Development (R&D) Team works from a unique angle to support CHAI’s ambitions to improve patient outcomes in low- and middle-income countries. In particular, the team works to: 1. Identify, develop, validate, and transfer for manufacture and distribution better and less expensive drug formulations of existing HIV/AIDS, tuberculosis (TB), and malaria medicines; 2....
Read more
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV London, May 26, 2015 – ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA)...
Read more
An agreement announced today will reduce the achievable cost per use of the non-pneumatic anti-shock garment (NASG) by over 75 percent and expand access to this innovative new product, which has been shown to safely and effectively reduce mortality due to post-partum hemorrhage, a leading cause of the nearly 290,000 maternal deaths reported annually around the world.
Read more
Clinton Health Access Initiative, Inc. Donor Disclosure Policy – Q & A April 16, 2015 Q: Why is CHAI’s policy different from the Clinton Foundation’s policy? CHAI is an independent 501c3 charitable organization, separate from the Clinton Foundation. CHAI operates in over 30 countries and has nearly 1,500 employees, over 80 percent of whom are...
Read more